Sanara posts strong revenue and 92% gross margin but higher debt, losses as it builds THP

Sanara MedTech Inc. (OTCMKTS: SMTI) - Quick take

What's happening: revenue and gross profit accelerated in H1 2025 while the company invests heavily in its THP value‑based wound‑care buildout and strategic investments; debt and interest costs rose sharply after the CRG term loan and several acquisitions/investments.

Key numbers & facts (as reported, June 30, 2025)

* Net revenue (Q2 2025): $25,830,834 (up 28% YoY from $20,158,823)

* Net revenue (YTD 6/30/25): $49,264,930 vs $38,695,461 (YTD 2024) - +27%

* Gross profit (Q2 2025): $23,893,552 - implied gross margin ≈ 92.5%

* Gross profit (YTD): $45,492,681 - implied gross margin ≈ 92.4%

* Net loss (Q2 2025): $(2,018,398); Net loss (YTD): $(5,545,781)

* Net loss per share (Q2): $(0.23); (YTD): $(0.64)

* Cash (6/30/25): $16,958,744 (beginning of period $15,878,295)

* Total assets: $98,767,645; Total liabilities: $63,375,699; Total equity: $35,391,946

* Long‑term debt, net (6/30/25): $44,216,662 (CRG Term Loan principal & accreted items)

* Accounts receivable, net: $11,989,698; Inventory: $3,511,850

* Intangible assets, net: $40,992,568; Goodwill: $3,601,781

* Investments in equity securities: $10,515,812 (includes ChemoMouthpiece, BMI, SI Tech)

* Cash flow (6 months): operating activities provided $665,127; investing used $(9,107,823) (CarePICS, BMI, investments, capex); financing provided $9,523,145 (term loan proceeds)

* Earnout / contingent consideration balance (6/30/25): $2,150,604 (includes CarePICS and Applied adjustments)

Inside the business - what's driving results

* Product momentum: Sanara Surgical drove nearly all revenue - soft tissue repair products (Q2: $22.66M) and bone fusion (Q2: $3.14M).

* THP (Tissue Health Plus) is in investment/pilot stage: minimal SaaS revenue ($26,582 in Q2) but meaningful operating losses - Segment Adjusted EBITDA Q2: Sanara Surgical $4.72M vs THP $(2.05)M.

* M&A & strategic investments: CarePICS acquired (April 2025), continued investment in BMI (initial €3.0M plus follow‑on), $5M minority in ChemoMouthpiece - these expand tech and pipeline but consumed cash and added earnouts/debt.

* Capitalization of internal software/tech: $3.4M capitalized for THP platform (part of property & equipment spike to $8.9M from $432k year‑over‑year).

Positive aspects of the income statement

* Strong top‑line growth: revenue up ~28% YoY in Q2 and ~27% YTD; growth driven by core products (CellerateRX Surgical, BIASURGE).

* Exceptionally high gross margins (~92%) - cost of goods sold is small relative to sales, indicating product-level profitability and pricing/COGS efficiency.

* Operating cash flow turned positive in H1 2025 (provided $665k) despite investments - showing improving working capital dynamics versus prior year negative operating cash flow.

Negative aspects of the income statement / risks

* Persistent net losses: Q2 loss $(2.02M), YTD loss $(5.55M); company remains unprofitable as it scales and builds THP.

* Heavy operating expenses: SG&A and R&D rose materially (six‑month SG&A $42.99M) to support sales expansion and THP build - compresses operating income despite strong gross profit.

* Rising interest expense: Q2 interest expense $1.79M (YTD $3.11M) following the CRG Term Loan - increased leverage is a recurring drag on profitability.

* Significant leverage: long‑term debt (~$44.2M) vs cash ~$17.0M - refinancing risk, covenant exposure and interest burden are material considerations.

* Investing cash burn: substantial investing outflows in H1 (≈$9.1M) for acquisitions and platform development; future burn depends on THP monetization and further milestones (BMI).

Operational & balance sheet issues to watch

* Debt covenants and revenue targets: CRG facility requires escalating annual minimum revenue targets ($75M for 2025) - management reports compliance as of 6/30/25 but continued revenue execution is critical.

* Earnouts and contingent liabilities: CarePICS and Applied earnouts add future cash or equity dilution risk (combined caps noted in filings).

* Working capital: AR is material (~$12M) and inventory increased; credit loss reserve ~$1.16M-collections and margin retention matter for cash flow.

* Integration execution: CarePICS, BMI and other investments must be integrated for THP and distribution strategies to generate expected returns.

Analyst summary - straight to the point

* Sanara (OTCMKTS: SMTI) shows healthy product demand and excellent gross margins, driving meaningful revenue growth.

* The company is choosing growth and capability building (THP platform, software, strategic minority stakes) at the cost of near‑term profitability and higher leverage.

* The main positives: strong revenue momentum, product gross profitability, and investments that could create recurring tech/SaaS revenue over time.

* The main negatives: elevated SG&A and interest burden, substantial debt (CRG loan), ongoing net losses and significant cash used for acquisitions and investments - execution risk on THP monetization and covenant compliance remains key.

Bottom line: revenue growth and a very high gross margin make Sanara interesting; the near‑term story is execution - convert THP investments and acquisitions into recurring cash flow while managing debt costs. Monitor quarterly operating cash flow, interest expense, earnout obligations, and whether THP pilot converts to meaningful recurring revenue.